34 results about "Posterior capsule opacification" patented technology

The present invention relates to methods and apparatus for preventing or treating posterior capsular opacification in a subject in need of prophylaxis or treatment for posterior capsular opacification, including a subject undergoing cataract surgery by ablating epithelial cells on an interior surface of the lens capsule with a multi-photon laser system.

The invention relates to a intraocular lens. At present the Poly-Methyl Methacrylate (PMMA) intraocular lens conventional for clinical treatment of cataract always causes inflammatory treaction after implantation. Posterior capsule opacification is also a major compalication after cataract surgery. The invention selects fluorouracil to solve the above problems. Based on weak penetrating force of chitosan nanoparticles in eyes and the relation between the phagocytosis amount of conjunctival epithelial cells to nanoparticles and the particle size of nanoparticles, the fluorouracil nanoparticles preparation is prepared using chitosan-poly(acrylic acid) as carrier, composite coated on the surface of PMMA intraocular lens. The invantion also provides a preparation method thereof. The said intraocular lens not only increases the biocompatibility of the intraocular lens, but also inhibites posterior capsule opacification pafter cataract surgery. The said intraocular lens can also prevent anterior membrane after implantation of intraocular lens and after-cataract.

An intraocular lens (IOL) for implantation within a capsular bag includes an optic and a plurality of haptics. The optics has an anterior optic face and a posterior optic face joined by a peripheral wall. The peripheral wall includes a straight portion of uniform width extending posteriorly from the anterior optic face to a flare point and a flared optic edge. The flared optic edge extends posteriorly and widens from the flare point and meets the posterior optic face at a sharp optic corner. Each of the haptics is coupled to the optic at the peripheral wall at respective haptic-optic junctions. The flared optic edge surrounds the peripheral wall between the haptic-optic junctions.

The present invention relates to amphiphilic block copolymers comprising at least one block of hydrophilic units and at least one block of hydrophobic units, wherein at least one hydrophobic block contains siloxane units. The present invention may be particularly useful as a tissue adhesive or as a coating for an intraocular lens (IOL). As an IOL coating, copolymers according to the invention may be used, for example, to promote tissue adhesion for the prevention of posterior capsule opacification.

Inhibitors of myosin activity are used to treat or prevent a fibrotic disorder of the eye, for example posterior capsule opacification (PCO).

The invention discloses a drug-carrying type artificial lens capable of being opened by a laser. The drug-carrying type artificial lens capable of being opened by the laser comprises an artificial lens main body, a plurality of drug storing holes with preset intervals are formed in the peripheral surface of the artificial lens main body, and micro-capsules loading active drug and capable of being punched through or resolved by the laser are embedded in the drug-storing holes. A plurality of drug micro-capsules are embedded into the peripheral portion of the artificial lens, the lens is opened to release by the laser on a suitable opportunity to achieve a treatment goal, and relative to a drug sustained releasing system, side effects brought by long-term sustained drug releasing is avoided. Besides the treatment goal of post-operation inflammatory resistance and posterior capsule opacification resistance, the drug-carrying type artificial lens capable of being opened by the laser can be embedded to achieve the purpose of controlling eye diseases aiming at certain diseases of age related macular degeneration, diabetic retinopathy and the like together with the complication of a cataract, and the complications caused by multiple injections of a vitreous cavity and the side effects of systemic administration are avoided or reduced.

The invention discloses a drug-modified intraocular lens and a preparation method and application thereof. According to the intraocular lens, by researching the effect of a signal path on proliferation and migration of lens epithelial cells, a drug with a prevention and treatment effect on posterior capsule opacification after cataract surgery is screened out. It is found that an inhibitor of a ROCK signal path has an influence on the proliferation and migration of the lens epithelial cells, and the drug-modified intraocular lens is provided by improving a drug feeding mode. The intraocular lens can relatively controllably release the explosive drug in the early stage; moreover, by slowly releasing the drug in the later stage, the intraocular lens integrally has the advantages of great biocompatibility and good prevention and treatment effect.

The invention aims to provide a miRNA and an application of miRNA in preparation of a product for diagnosing and treating posterior capsule opacification. The miRNA is miR-204-5p and the RNA sequence is SEQ ID NO:1. A miRNA gene product can be used for adjusting the expression of an SMAD4 gene, blocking a TGF (Transforming Growth Factor)-beta/Smads signal channel and inhibiting epithelial-mesenchymal transition (EMT), and has the potential of preparing the diagnosing and treating product for the posterior capsule opacification PCO.

The present invention provides a long-acting heparin intraocular slow-releasing system, including heparin and medicinal carrier; their weight ratio is 0.1:0.9-0.9:0.1. Said medicinal carrier can be synthetic biodegradable high-molecular material, natural biodegradable high-molecular material or their mixture. The medicine-releasing period of said invented long-acting heparin slow-releasing systemis one week to one year. It can be used for inhibiting formation of antithrombase, resisting conversion of fibrinogen into insoluble fibrin, inhibiting proliferation and chemotaxis of fibrolast, reducing postoperative fibrinous exudation and preventing postcapsule opacity so as to inhibit the production of after-cataract.

Described is an accommodating intraocular lens with a bi-convex, bi-aspheric, smooth surfaced optic held inside an anterior annulus via tabs. A second larger diameter annulus is positioned posteriorly and connects via a sloped surface to where the annuluses are at a maximum separation when viewing NEAR objects and minimum separation in the FAR position. The sloped surface is cut into ribbons, tabs and/or other annuluses without pushing the surfaces into the capsule when implanted; therefore, only the anterior and posterior annuluses have a force component against the capsule. The proximal edge of the anterior annulus is anterior to the apex of the anterior surface of the optic. The anterior capsule resting on the annulus leaves space for hydration of the capsule and reduces potential warpage of the optic. The annulus edge is designed to scrape posterior capsular opacification from the capsule.

The invention provides an active isaria cicadae miquel substance and an application thereof in prevention, delaying or treatment of cataract, and belongs to the technical field of active substances. A preparation method of the active isaria cicadae miquel substance comprises steps as follows: isaria cicadae miquel strains activated in a PDA (potato dextrose agar) slant medium are inoculated into a seed solution medium for culture, and a seed solution is obtained; the seed solution is inoculated into a PDA liquid medium containing traditional Chinese medicine extract and Cajanonic acid A for culture, then mycelia and fermentation liquor are dried and smashed, and a fermented product containing the active substance is obtained; the fermented product is extracted in distilled water, an extracting solution is obtained and concentrated into extractum, the extractum is dried, and the active isaria cicadae miquel substance is obtained. Active ingredients in the active isaria cicadae miquel substance obtained with the preparation method can play the gain role, and the active isaria cicadae miquel substance has a protecting effect, delays the pathological process of posterior capsule opacification, delays development of cataract and is expected to be applied to prevention and treatment of age-related cataract and after cataract.

The invention relates to an artificial lens with a hydrophilic-medicine sustained release synergistic function, and a preparation method thereof. A medicine-loading-hydrophilic multifunctional coatingis modified on the surface of the artificial lens, and the synergistic effect of resisting cell adhesion at an early stage after implantation and resisting lens epithelia cell proliferation at middleand late stage is achieved, so that the occurrence rate of posterior capsule opacification can be reduced and a high-biocompatibility artificial lens is obtained; a hydrophilic-medicine-loading multifunctional modification layer is constructed on the surface of the artificial lens by a one-pot method, the manufacturing process is simple and low in cost, the tedious steps required by surface modification in the past are avoided, and the artificial lens can be applied to the surface of a three-dimensional implantable device with various complex shape structures. The manufactured zwitterionic modified artificial lens is convenient to disinfect, packaging and transport, and is an artificial lens industrialized product which is low in cost, convenient and practical.

In various embodiments, ocular treatment systems, intraocular lenses, and treatment methods are utilized for the treatment or prevention of posterior capsule opacification of the eye by, for example, targeting portions of the posterior lens capsule for ablation while minimizing damage to implanted intraocular lenses.

The invention provides pirenoxine sodium eye drops. According to an embodiment of the invention, the pirenoxine sodium eye drops comprise a solvent, an anti-inflammatory agent, and a solid preparation, wherein the solid preparation contains pirenoxine sodium and pharmaceutically acceptable auxiliary materials. According to the embodiment of the invention, the pirenoxine sodium eye drops contain the anti-inflammatory agent and the pirenoxine sodium at the same time, so that the pirenoxine sodium eye drops can be applied to eye administration in the initial stage after an operation of a patient, the eye infection can be effectively prevented, the incidence rate of posterior capsule opacification after the operation can be reduced, especially, the occurrence rate of posterior capsule opacification after extracapsluar cataract extraction is reduced, the curing time of eye cataract of the patient can be shortened, the pain of the patient is reduced, and the living quality of the patient is improved.

It is disclosed here that actin-disrupting compounds and 1-(5-isoquinolinyl-sulfonyl)-2-methylpiperazine can be used to facilitate the removal of lens epithelial cells from the lens capsule during cataract surgery and they may also be used to inhibit lens epithelial cells' proliferation and/or migration after surgery to reduce the risk or severity of posterior capsular opacification. Various related methods, kits, and ocular implants for reducing the risk or severity of posterior capsular opacification are provided.

Generally, an intraocular implant having on the external surface a plurality of pattern surface elements disposed in spaced apart relation defining a tortuous pathway adapted to control a flow of fluid or a flow of particles suspended in a fluid or inhibit the growth or migration of cells is provided. In particular, an intraocular implant that is implanted between an intraocular lens and the surface of the posterior capsule of the eye inhibits growth or migration of residual lens epithelial cells after cataract surgery by providing structural barriers to reduce posterior capsule opacification of the eye.

The invention relates to an ophthalmic controlled release system of long-action low molecular heparin which comprises the low molecular heparin as drug and a drug carrier made from synthesized or natural biodegradable high molecular materials and is characterized in that the proportion range of the low molecular heparin and the drug carrier is (1:8) to (5:1); the average molecular mass of the low molecular heparin is less than 8000 Dalton; the molecules less than 8000 Dalton, the salt compounds of the low molecular heparin such as sodium salt, calcium salt and kali salt included, take up not less than 60 percent of the total molecules of the low molecular heparin; the synthesized or natural biodegradable high molecular materials are polyglycolic acid and gelatin or bletilia striata gelatin respectively. The ophthalmic controlled release system of long-action low molecular heparin can effectively inhibit the proliferation and migration of lenticular epithelia and fibroblasts in eyes, reduce fibrinous exudates post operation, alleviate inflammatory reaction post operation and prevent posterior capsular opacification, thereby inhibiting the occurrence of after-cataract; meanwhile, the ophthalmic controlled release system of long-action low molecular heparin inhibits the proliferation of retinal pigment epithelium and fibroblasts, thus inhibiting the proliferative vitreoretinopathy (PVR).